Hematopoietic stem cell biology And leukemogenesis

Summary

Hematopoietic stem cells (HSCs) are considered the base of adult hematopoiesis. Currently, most of these hematological disorders are curable by HSC transplantation. However, the limited availability of optimally human matched donor remains a challenge, especially for individuals of non-Caucasian background or mixed ethnicity. Human pluripotent stem cells (PSCs), including embryonic stem cells (hESCs) and induced PSCs (hiPSCs), can differentiate in vitro into various hematopoietic cell type and could represent an ideal source of customized HSCs for clinical application. Furthermore, HSCs derived from patient-iPSCs not only represent an invaluable hematological disease modeling but might provide a cell-based platform for therapeutic screening. The production of engrafting HSCs from human PSCs will depend on the accurate recapitulation of embryonic hematopoiesis.

23 Publications

Hematopoietic-Stem-Cell-Biology-And-Leukemogenesis

Strategic lines

Selected Publications

- Bigas A, Palma LG, Kartha GM, Giorgetti A. Using Pluripotent Stem Cells to Understand Normal and Leukemic Hematopoietic Development. Stem Cells Transl. Med. 2022. doi: 10.1093/stcltm/szac071

- Kotmayer L, Romero Moya D, Marin Bejar O, Kozyra E, Català A, Bigas A, Wlodarski MW, Bödör C, Giorgetti A. GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects. Br J Haematol. 2022;199(4):482-495. doi:10.1111/bjh.18330.

- Pera J, Castaño J, Casamitjana J, Giorgetti A, Romero Moya D. Generation of heterozygous SAMD9 CRISPR/Cas9-edited iPSC line (ESi086-A-3), carrying p.I1567M mutation. Stem Cell Res. 2022;64102906-102906. doi:10.1016/j.scr.2022.102906. IF:1,59.

- Castaño J, Romero Moya D, Richaud Patin Y, Giorgetti A. Generation of two heterozygous GATA2 CRISPR/Cas9-edited iPSC lines, R398W and R396Q, for modeling GATA2 deficiency. Stem Cell Res. 2021;55102445-102445. doi:10.1016/j.scr.2021.102445. IF:2,02.

- Maroni G, Bassal MA, Krishnan I, Fhu CW, Savova V, Zilionis R, Maymi VA, Pandell N, Csizmadia E, Zhang JY, Storti B, Castano J, Panella R, Li J, Gustafson CE, Fox S, Levy RD, Meyerovitz CV, Tramontozzi PJ, Vermilya K, De Rienzo A, Crucitta S, Basseres DS, Weetall M, Branstrom A, Giorgetti A, Ciampi R, Del Re M, Danesi R, Bizzarri R, Yang H, Kocher O, Klein AM, Welner RS, Bueno R, Magli MC, Clohessy JG, Ali A, Tenen DG, Levantini E. Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer. Commun Biol. 2021;4(1):370-370. doi:10.1038/s42003-021-01897-6. IF:6,27.

Selected Projects

FORT23/00032_6. Smart Health Community (SHC), promoviendo la medicina basada en el valor. Instituto de Salud Carlos III (ISCIII). Budget: 416.864€. 2024-2028. PI: GIORGETTI, ALESSANDRA.
AC23_2/00040. 3D-GATA2: How GATA2 Deficiency affects development and disease. Instituto de Salud Carlos III (ISCIII). Budget: 180.000€. 2024-2027. PI: GIORGETTI, ALESSANDRA.
PID2023-146290OB-I00. Estudio del Papel del Nicho de Médula Osea en la Deficiencia de GATA2. Ministerio de Ciencia e Innovación. Budget: 318.750€. 2024-2027. PI: GIORGETTI, ALESSANDRA.
DJCLS 13R/2022. Die Untersuchung genetischer und mechanistischer Auswirkungen einer Monosomie 7 bei der GATA2 Defizienz (Investigating genetic and mechanistic contributions of monosomy 7 in GATA2 deficiency). DEUTSCHE JOSÉ CARRERAS LEUKÄMIE-STIFTUNG E.V. Budget: 130.100€. 2022-2025. PI: GIORGETTI, ALESSANDRA.
202001-32. New approaches for the identification and functional characterization of prognostic genetic biomarkers in inherited childhood myelodysplastic/acute leukemia syndromes”. Fundació La Marató de TV3. Budget: 142392,18€. 2021-2024. PI: GIORGETTI, ALESSANDRA.